# US 2024/0391901 A1 · Substituted heterocyclic compound containing alpha-ketone framework, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0391901 A1
- Document ID: US20240391901A1
- Status: Published application
- Kind: A1
- Application number: 18/694,448
- Filed: 2022-09-23
- Published: 2024-11-28
- Earliest claimed: 2021-09-24
- Assignees: China Pharmaceutical University
- Applicants: China Pharmaceutical University
- Inventors: Jinxin Wang; Lili Li; Tao Meng; Yanguo Shang; Qingjing Hao; Yihe Jia
- Web page: https://patentgrep.com/patent/US20240391901A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 25/36: Opioid-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/20: for DNA viruses
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed in the present invention are a substituted heterocyclic compound containing an α-ketone framework, and the use thereof, which relate to the field of medicinal chemistry. Specifically disclosed are a substituted heterocyclic compound containing an α-ketone framework, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing these compounds, and the medical use thereof, and in particular, the use thereof as a fatty acid amide hydrolase (FAAH) inhibitor in the preparation of a drug for preventing or treating FAAH-related diseases, comprising inflammatory diseases, rheumatoid arthritis, hepatitis, hepatic fibrosis, autoimmune disease, pain, depression, pain and depression comorbidity, autism, social anxiety disorder, Tourette's syndrome, neurode-generative diseases, anxiety and post-traumatic stress disorder (PTSD), cannabinoid use disorders, drug withdrawal and anti-tumor treatment.

## Claims

### Claim 1

A compound as shown in formula I or a pharmaceutically acceptable salt thereof:
wherein,
Ar is an unsubstituted, monosubstituted, or polysubstituted heteroaromatic ring; wherein the heteroaromatic ring is selected from: furan, thiophene, pyrrole, oxazole, isoxazole, imidazole, pyrazole, thiazole, isothiazole, triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-oxadiazole, 1,2,4-thiadiazole, pyridine, pyrimidine, pyridazine, benzoxazole, benzothiazole, purine, quinoline, isoquinoline, indazole, oxazolo[4,5-b]pyridine, and oxazolo[5,4-b]pyridine;
R1 represents H or aryl or heteroaryl;
L represents a linker, selected from —O—, —S—, —NR4—,
n=0, 1, 2, 3;
R4 is selected from H, C1-C8 straight or branched halogenated alkyl, halogenated cycloalkyl, C1-C8 straight or branched alkyl, cycloalkyl;
is selected from
R2 is selected from H, methyl, ethyl, acetyl, phenyl, pyridyl, methoxycarbonyl, propionyl, methoxyacetyl, and ethoxyacetyl;
R3 is selected fromH, F, Cl, Br, I, CF3, CN, hydroxyl, methoxy, methyl, nitro, thiol, carboxyl, vinyl, bromomethyl, cyanomethyl, aryl, heterocyclyl, C1-C10 straight or branched alkyl, cycloalkyl, C1-C10 straight or branched alkyl substituted thiol group, C1-C10 straight or branched alkyl ester group.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The compound according to claim 1, wherein, the heteroaromatic ring is selected from the following groups:

### Claim 4 (depends on 1)

The compound according to claim 1, wherein, R1 represents H, aryl or heteroaryl; wherein the aryl or heteroaryl is unsubstituted, monosubstituted, or polysubstituted, the aryl or heteroaryl is selected from phenyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, isooxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, triazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,2,4-thiadiazolyl, pyridinyl, pyrimidinyl, pyridazinyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, indazolyl, benzoxazolyl, benzothiazolyl, purinyl, oxazolopyridinyl; the substituent on the aryl or the heteroaryl is selected from H, F, Cl, Br, I, CF3, CN, hydroxyl, methoxy, methyl, nitro, thiol, carboxyl, vinyl, bromomethyl, cyanomethyl, C1-C10 straight or branched alkoxy, C1-C10 straight or branched halogenated alkyl, halogenated cycloalkyl, C1-C10 straight or branched alkyl, cycloalkyl, C1-C10 straight or branched alkyl substituted thiol group, C1-C10 straight or branched alkyl amide group, C1-C10 straight or branched alkyl ester group.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein,
R1 is selected from
the substituent on R1 is selected from H, F, Cl, Br, I, methoxy, and methyl.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein,
L is —CO—;
and/or, R2 is selected from H, and methyl;
and/or, R3 is selected from H, F, Cl, Br, and I.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein,
is selected from

### Claim 8

A compound or a pharmaceutically acceptable salt thereof, selected from:

### Claim 9 (depends on 1)

A method for preventing and/or treating a FAAH-related disease in a subject in need thereof, comprising administering the compound of formula I or the pharmaceutically acceptable salt thereof according to claim 1.

### Claim 10 (depends on 9)

The method according to claim 9, wherein, the FAAH-related disease comprises inflammatory disease, rheumatoid arthritis, hepatitis, hepatic fibrosis, autoimmune disease, pain, depression, pain and depression comorbidity, autism, social anxiety disorder, Tourette's syndrome, neurode-generative disease, anxiety and post-traumatic stress disorder, cannabinoid use disorders, drug withdrawal and anti-tumor treatment.

### Claim 11 (depends on 8)

A method for preventing and/or treating a FAAH-related disease in a subject in need thereof, comprising administering the compound of formula I or the pharmaceutically acceptable salt thereof according to claim 8.

### Claim 12 (depends on 11)

The method according to claim 11, wherein, the FAAH-related disease comprises inflammatory disease, rheumatoid arthritis, hepatitis, hepatic fibrosis, autoimmune disease, pain, depression, pain and depression comorbidity, autism, social anxiety disorder, Tourette's syndrome, neurode-generative disease, anxiety and post-traumatic stress disorder, cannabinoid use disorders, drug withdrawal and anti-tumor treatment.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein,
Ar is selected from pyrrole, oxazole, isoxazole, imidazole, pyrazole, thiazole, isothiazole, triazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,2,4-oxadiazole, 1,2,4-thiadiazole, benzoxazole, benzothiazole, purine, quinoline, indazole, oxazolo[4,5-b]pyridine, and oxazolo[5,4-b]pyridine.

### Claim 14 (depends on 1)

The compound according to claim 1, wherein,
R1 is H, phenyl, furanyl, thiophenyl, and pyridinyl; the substituent on the phenyl, furanyl, thiophenyl, and pyridinyl is selected from H, F, Cl, Br, I, C1-C10 straight or branched alkoxy, C1-C10 straight or branched halogenated alkyl, and C1-C10 straight or branched alkyl.
